Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162300 · ClinicalTrials.gov registry record · Phase 4
Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles
A Phase 4 study of Wrinkle and Photoaging, sponsored by Vitality Institute Medical Products.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05162300: Completed Phase 4 study of Wrinkle and Photoaging, sponsored by Vitality Institute Medical Products.
NCT05162300 is a Phase 4 study of Wrinkle and Photoaging that has completed, run by Vitality Institute Medical Products. The registered enrollment target is 30 participants, below the 119-participant average among 25 other Wrinkle trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05162300, a Phase 4 study of Wrinkle and Photoaging, has completed, sponsored by Vitality Institute Medical Products.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to improve standards of care in the cosmetic treatment of sun damage, fine lines, and wrinkles. VI Peels® and Botox® have been used cosmetically to improve patient concerns as monotherapies. This study seeks to confirm that the same-day combination creates no additional side-effects and furthermore that patient satisfaction is heightened as a result.
Primary Outcome
To establish safety of the same-day combination of VI Peel \& Botox, the study will measure the rate and occurrence of Adverse Events as compared to a stand-alone treatment of Botox. Rate and occurrence of Botox as a stand-alone intervention will be based off of the package insert indicating each Adverse Event
Conditions Studied
Interventions
- COMBINATION_PRODUCT Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
Study Locations (1)
California
- Dr. Wendy E. Roberts, MD - Rancho Mirage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-08 |
| Est. Completion | 2022-02-01 |
| Phase | Phase 4 |
What the finished NCT05162300 record still lists
NCT05162300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 119-participant average among 25 other Wrinkle trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Wrinkle appearing as the primary indexed condition, and to 1 intervention - of which Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug) is the first listed.
NCT05162300 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05162300 about?
NCT05162300 is a clinical study titled "Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles". This study is being conducted to improve standards of care in the cosmetic treatment of sun damage, fine lines, and wrinkles. VI Peels® and Botox® have been used cosmetically to improve patient concerns as monotherapies. This study seeks to confirm that the same-day combination creates no additional...
What is the current status of trial NCT05162300?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2021-12-08. Estimated completion is 2022-02-01.
What conditions does trial NCT05162300 study?
This clinical trial studies the following conditions: Wrinkle, Photoaging, Sun Damaged Skin.
What interventions are being tested in trial NCT05162300?
The interventions under investigation include: Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05162300?
This trial is sponsored by Vitality Institute Medical Products, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05162300 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wrinkle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05162300's enrollment target sits among peer trials
30 18th of 25 higher than 8 of 25 other Wrinkle trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wrinkle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles
RECRUITING · NA
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation
RECRUITING
-
Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions
RECRUITING · NA
-
The Effects of Almond on Facial Skin Collagen and Wrinkles
RECRUITING · NA
-
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI